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Abstract
Background: Ovarian carcinoma is the fourth most common cause of death from cancer in women. Limited
progress has been made toward improving the survival rate of patients with this disease in part because of the lack
of a good animal model. We present here a model of spontaneous ovarian carcinoma arising in a normal Lewis rat.
Methods: A spontaneously occurring tumor of the left ovary was found in a normal Lewis rat during necropsy,
which was sectioned for histological examination and placed into single cell suspension. Tumor cells were
passaged in vivo by intraperitoneal injection into immunocompetent Lewis rats, and in vitro culture resulted in
generation of a cell line. Tumor cells were examined by flow cytometry for expression of estrogen receptor a,
progesterone receptor, androgen receptor, her-2/neu, epithelial cell adhesion molecule, and CA125. b-catenin
expression and cellular localization was assessed by immunocytochemistry. RNA was harvested for gene expression
profiling and studying the expression of cytokines.
Results: The tumor, designated FNAR, could be serially transplanted into Lewis rats and propagated as a cell line
in vitro, maintaining the properties of the original tumor. The FNAR cells displayed striking morphologic similarities
to human ovarian carcinoma, resembling the endometrioid carcinoma subtype of surface epithelial neoplasms. The
cells expressed estrogen receptor a, progesterone receptor, androgen receptor, her-2/neu, epithelial cell adhesion
molecule, CA125, and nuclear b-catenin. A gene expression profile showed upregulation of a number of genes that
are also upregulated in human ovarian carcinoma.
Conclusion: This reliable model of ovarian carcinoma should be helpful in better understanding the biology of the
disease as well as the development of novel treatment strategies.
Background
Ovarian cancer is the fifth most commonly diagnosed
cancer in women and the fourth most common cause of
death from cancer [1]. The high mortality can be attrib-
uted to the high percentage of affected women present-
ing at an advanced stage, with spread within the
peritoneal cavity [2,3]. With current therapies, including
surgical debulking and platinum-based chemotherapy,
patients in stage III or stage IV only have a 20% chance
of long-term survival [2,3]. Better understanding ovarian
carcinoma biology, as well as the development of new
therapies for the disease, has been hampered by the lack
of suitable animal models.
Current ovarian cancer models fall into three broad
categories: rare spontaneous carcinomas, induced
tumors, and human xenografts [4]. Although these
models have allowed researchers to gain valuable
insights into the biology of ovarian cancer, each model
exhibits important limitations [4,5]. Spontaneous ovar-
ian cancer has been observed in mice, rats, and hens
[6-8]. The drawback to these models is that the can-
cers tend to occur at an advanced age and at similar
low frequencies as in humans. The low incidence and
the length of time required for the development of
these tumors render them of limited use for studying
the biology and treatment of ovarian carcinoma.
Induced tumor models circumvent these problems but
create their own artificial systems, which may not
accurately reflect the human disease. In one model of
in vitro transformation, ovarian surface epithelium
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tact inhibition, the capacity for substrate-independent
growth, cytogenetic abnormalities, and the ability to
form tumors when injected subcutaneously and/or
intraperitoneally into athymic mice [9]. This model,
though, fails to account for critical interactions
between the cancer cells and the host. Also, it is
uncertain if these cells or their malignant transforma-
tion are representative of normal human cells or clini-
cal disease.
Animal models have been generated by expressing
simian virus 40 large T antigen [10], by inactivating
p 5 3a n dR b 1[ 1 1 ] ,b yi n a c t i vating p53 and activating
an oncogene [12], and through hormone treatment
[13-15]. The high rate of cancer development in these
animals makes these models attractive, but they may
not reliably represent human cancer because a major-
ity of these genetic changes usually do not occur in
patients. Xenografts of human cancers have under-
gone continuous improvement over the past twenty
years [16-19]. These models allow for direct examina-
tion of the human cancer but do not allow the study
of the early stages of the cancer. These models also
rely on an immune-deficient host, which eliminates
the interaction between the cancer and the immune
system.
We present a new model of ovarian carcinoma, desig-
nated FNAR, that spontaneously developed in an
untreated, previously normal Lewis rat. The tumor
could be serially passaged both in vivo as malignant
ascites in rats and in vitro. Importantly, the biologic
characteristics of the tumor closely paralleled one type
of human ovarian carcinoma.
Methods
Animals
Female Lewis strain rats aged 4-6 weeks (purchased
from Charles River Breeding Laboratories, Inc., Wil-
mington, MA) were kept in sterile micro-isolator cages
and fed food and water ad libitum. The institutional
guidelines of Johns Hopkins University concerning the
care and use of research animals were followed. The
animals were challenged intraperitoneally with graded
numbers of FNAR cells and monitored daily for abdom-
inal swelling. At various intervals after tumor challenge
or when animals appeared moribund (pallor, lethargy,
and marked abdominal distension), the animals were
sacrificed by CO2 asphyxiation and the cells within the
peritoneal cavity harvested by flushing the abdomen
with 35 milliliters of sterile phosphate buffered saline
( P B S ,G r a n dI s l a n dB i o l o g i c a lC o . ,G i b c oB R L ,G r a n d
Island, NY). At sacrifice, the animals were examined for
tumor growth and tissues taken for histological
examination.
In vitro propagation and growth curve
Ac e l ll i n e( F N A R )t h a tg r o w sin vitro as an adherent
monolayer was established by culture in RPMI 1640
(Gibco) supplemented with 10% fetal calf serum in 30
ml tissue culture flasks (Corning Flask 3056, Corning
Inc., Corning NY). Cells used for experiments were low
passage and maintained in culture for one to three
months. The doubling time of the cell line was mea-
sured by plating 10
4 cells into macrotiter wells then har-
vesting and counting at 19.5, 43.5, and 115.5 hours.
Flow Cytometric Analysis
Flow cytometry was utilized to assess in vitro FNAR
cells for expression of known phenotypic markers.
Briefly, 5 × 10
5 tumor cells were incubated in polystyr-
ene tubes. Analysis of the intracellular antigens estrogen
receptor a, progesterone receptor, and androgen recep-
tor first required fixation in 2% formaldehyde (Poly-
sciences, Warrington, PA) in phosphate buffered saline
(PBS, Gibco Invitrogen, Carlsbad, CA) for 15 minutes at
4°C followed by permeabilization with 0.1% Triton-X-
100 (Sigma-Aldrich, St. Louis, MO) in PBS for 15 min-
utes at 4°C. The cells were then incubated for 30 min-
utes at 4°C with commercially purchased murine
monoclonal antibodies. The concentrations of antibodies
used are as follows: estrogen receptor (ER) a at 8 μg/
10
6 cells (Abcam, Cambridge, MA), progesterone recep-
tor (PR) at 16 μg/10
6 cells (Affinity Bioreagents, Golden,
CO), or androgen receptor (AR) at 2 μg/10
6 cells (Phar-
mingen, San Diego, CA). The cells were washed and
counterstained with phycoerythrin (PE) rat anti-mouse
IgG1 (Becton Dickinson, San Jose, CA) at 125 ng/10
6
cells for 30 minutes at 4°C. Commercially purchased
murine monoclonal antibody to the rat c-neu oncogene
product (Calbiochem, San Diego, CA) was used at 1 μg/
10
6 cells and was counterstained with PE rat anti-mouse
IgG2a+b (Becton Dickinson, San Jose, CA) at 30 ng/10
6
cells for 30 minutes at 4°C. Tumor cells incubated with
secondary antibody alone served as a negative control.
Epithelial cell adhesion molecule (EPCAM) expression
was analyzed using a PE-conjugated antibody (Santa
C r u z ,S a n t aC r u z ,C A )a t1μg/10
6 cells with mouse
IgG1-PE as a negative control (Becton Dickinson, San
Jose, CA). A commercially available rabbit polyclonal
antibody to CA125 (Abbiotec, San Diego, CA) was used
at 2 μg/10
6 cells and counterstained with 1 μg/10
6 cells
APC goat anti-rabbit IgG (Invitrogen Molecular Probes,
Carlsbad, CA). The cells were analyzed on a Becton-
Dickinson FACSCalibur flow cytometer and data was
analyzed using FlowJo (Tree Star, Inc, Ashland, OR).
Immunocytochemistry
FNAR cells were plated onto four-well CultureSlides
(BD Falcon, San Jose, CA). Cells were fixed in 2%
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meabilization in 0.5% Triton X-100 in PBS for 10 min-
utes. Cells were then incubated with a mouse
monoclonal antibody to beta-catenin conjugated to Cy3
(Abcam, Cambridge, MA) at 6 μg/ml for one hour and
counterstained with 500 ng/ml DAPI for five minutes
(Invitrogen Molecular Probes, Carlsbad, CA). Images
were captured using the Nikon Eclipse E800 (Tokyo,
Japan) at 200× magnification with standard filters for
DAPI and Cy3, the DS-QiMc digital camera (Nikon,
Tokyo, Japan), and the Advanced Research Elements AR
3.0 software (Nikon, Tokyo, Japan).
Gene Expression Analysis by cDNA Microarrays
RNA was extracted and purified from cell lysates of 1-5 ×
10
5 in vitro FNAR tumor cells and the REH cell line
of normal rat endothelial cells, as a control, with 500 μl
Trizol reagent (Invitrogen, Carlsbad, CA). Tissue samples
were frozen in liquid nitrogen and pulverized with a
mortar and pestle. The powder was dissolved in Trizol
and centrifuged. Purified RNA was dissolved in 20 μl
diethyl-pyrocarbonate-treated distilled water. The result-
ing RNA was analyzed at the Johns Hopkins microarray
core. RNA from control and experimental samples was
processed using the RNA amplification protocol
described by Affymetrix (Affymetrix Expression Manual).
Briefly, 5 μg of total RNA was used to synthesize first
strand cDNA using the SuperScript Choice System (Invi-
trogen, Carlsbad, California) and oligonucleotide primers
with 24 oligo-dT plus the T7 promoter (Proligo LLC,
Boulder, Colorado). Following the double stranded
cDNA synthesis, the product was purified by phenol-
chloroform extraction and biotinilated anti-sense cRNA
was generated through in vitro transcription using the
BioArray RNA High Yield Transcript Labeling kit
(ENZO Life Sciences Inc., Farmingdale, New York). Fif-
teen μg of the biotinilated cRNA was fragmented at 94°C
for 35 minutes in buffer (100 mM Tris-acetate, pH 8.2,
500 mM potassium acetate, and 150 mM magnesium
acetate), and 10 μg of total fragmented cRNA was hybri-
dized to the Affymetrix GeneChip rat 230 2.0 array
(Santa Clara, CA) for 16 hours at 45°C with constant
rotation (60 rpm). Affymetrix Fluidics Station 450 was
then used to wash and stain the chips with a streptavi-
din-phycoerythrin conjugate. The staining was then
amplified as follows: blocking was performed using goat
IgG, then a biotinilated anti-streptavidin antibody (goat)
was bound to the initial staining, and amplification was
completed by the addition of a streptavidin-phycoery-
thrin conjugate. Fluorescence was detected using the
Affymetrix 3000 7G GeneArray Scanner and image ana-
lysis of each GeneChip was done through the GeneChip
Operating System 1.4.0 (GCOS) software from Affyme-
trix using the standard default settings. For comparison
between different chips, global scaling was used to scale
all probesets to a user defined target intensity (TGT)
of 150.
Quantitative RT-PCR for Cytokine Expression
Quantitative RT-PCR (Taqman, Applied Biosystems,
ABI, Foster City, CA) was utilized to assess levels of
cytokine mRNA transcripts of in vitro FNAR cells as
previously described [20]. The oligonucleotide primers
and fluoresceinated probes for the cytokine genes (IL-6,
IL-12, and IL-18), ER, PR, and stathmin were purchased
from ABI. Data were analyzed in real-time with Sequen-
cer Detection version 1.6 software, with the results nor-
malized against mRNA transcripts for the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase
(GADPH).
Results
Description of proband
Examination of a normal female Lewis rat sacrificed for
harvesting normal splenic T cells showed a sponta-
neously occurring tumor (approximately 0.5 cm
3)
derived from the left ovary and attached to and invading
the abdominal wall (Figure 1A). In addition, tumor stud-
ding was observed at several sites on the wall of the
peritoneum, and ascites was present. Histologic evalua-
tion revealed an epithelial neoplasm with features most
consistent with an adenocarcinoma (Figure 1B). The
tumor was composed of nests displaying admixed cribri-
form and solid architecture. The tumor cells had modest
amounts of amphophilic/eosinophilic cytoplasm and
relatively uniform, moderately atypical oval nuclei that
were predominantly vesicular to modestly hyperchro-
matic with small nucleoli. Occasional mitotic figures
and apoptotic bodies were noted, as was focal necrosis.
Based on analogy to human ovarian epithelial tumors,
this tumor most closely resembled a moderately differ-
entiated endometrioid carcinoma (a cribriform variant
of that subtype, with cells being less columnar than the
classical human endometrioid carcinoma), with disease
distribution paralleling a typical high-stage (human
FIGO stage IIIB) ovarian carcinoma. Lymphocyte infil-
tration into the tumor mass was minimal at best,
although numerous lymphocytes were present in the
peritoneal fluid. The tumor was excised and pushed
through a 100 micron wire mesh screen to obtain a sin-
gle cell suspension.
In vivo and in vitro growth characteristics
Normal Lewis rats were given either intraperitoneal (IP)
or subcutaneous injection of graded numbers (5 × 10
4,
1×1 0
5,5×1 0
5,o r1×1 0
6) of tumor cells. The animals
were monitored daily for overall general health as well
as degree of abdominal extension. The tumor repeatedly
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tion of systemic immunosuppression (Cyclosporine,
10 mg/kg/d) or passage into thymectomized animals.
However, all rats became moribund at 150-160 days
after IP injection with 5 × 10
5 or 1 × 10
6 cells (Table 1).
Rats injected with 1 × 10
5 cells became moribund
around 175 days. Rats receiving IP injections of 5 × 10
4
cells generally did not appear ill by 6 months, but
tumor cells were detected in the peritoneal cavity when
sacrificed on day 175. Tumor growth recapitulated that
seen in the initial rat with IP tumoral masses adhering
to all of the visceral organs and the abdominal wall.
Histologically, the tumors appeared to be of epithelial
origin. Affected rats also showed enlargement of the
ovaries and fallopian tubes, with a marked increase in
vascularization. Successful serial passage was conducted
by IP challenge with 1 × 10
5 tumor cells harvested by
flushing of the peritoneal cavity.
The doubling time of the FNAR cell line was
measured by plating 10
4 cells into macrotiter wells then
harvesting and counting at 19.5, 43.5, and 115.5 hours
(Figure 2). The slope of the line of log number of
tumor cells versus hours estimates a doubling time of
22.9 hours.
Figure 1 Gross and histologic examination of proband. Intraperitoneal tumor arising spontaneously in a Lewis rat has pathologic appearance
of an ovarian adenocarcinoma. (A) Proband shows tumor of the left ovary and intraperitoneal tumor studding. (B) Histology reveals an
adenocarcinoma.
Table 1 Survival after intraperitoneal injection of
FNAR cells.
Survival Following Tumor Challenge
No. of Cells Injected No. of Animals Survival - Days
(No. of Animals)
5×1 0
4 N = 6 175 (6)
1×1 0
5 N = 8 150 (4) 155 (3), 160 (1)
5×1 0
5 N = 6 155 (2), 160 (4)
1×1 0
6 N = 6 150 (5), 152 (1)
The survival time of rats corresponds to the number of FNAR cells injected
intraperitoneally. Animals were observed daily for general health and
abdominal extension. The animals were sacrificed upon becoming moribund,
which was characterized by extreme lethargy, paleness, and abdominal
extension. The abdominal cavity was examined histologically for the presence
of tumor cells in the peritoneal fluid and for tumor masses attached to the
visceral organs and the abdominal wall.
Figure 2 In vitro growth characteristics. In vitro doubling time
was measured by plating 10
4 cells into large flat bottom macrotiter
wells. At the designated intervals, cells were harvested and counted.
Data is presented as log number of tumor cells versus growth time.
The slope of the line represents an estimate of the doubling time.
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ER is detected in 60-90% of ovarian carcinomas [21-25],
25-50% express PR [21,23-26], and 45% expressed both
[23,25]. AR is expressed in 50-70% of ovarian carcino-
mas [24,26]. Accordingly, in the appropriate clinical and
pathologic setting, sex hormone receptor expression is
characteristic of ovarian carcinoma [25,27]. The tumor
expressed ER, PR, and AR by flow cytometry (Figure
3A-C), with ER and PR confirmed by PCR (data not
shown). The tumor also expressed her-2/neu (Figure
3D), which is expressed in 25-35% of ovarian carcino-
mas [28,29]. The epithelial origin of this carcinoma was
confirmed by its expression of EPCAM (Figure 3E).
Consistent with previous reports of endometrioid carci-
noma, FNAR cells display cell-surface expression of
CA125 (MUC16, data not shown) [30]. FNAR cells also
Figure 3 FNAR expression of ER, PR, AR, Her-2/neu, and EPCAM. Flow cytometric evaluation of FNAR cells for expression of (A) ER, (B) PR,
(C) AR, (D) Her-2/neu, and (E) EPCAM. In all five graphs, isotypic control is shown with a solid line and the antibody of interest is shown with a
shaded area.
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strongly associated with the endometrioid subtype [31].
Gene expression profiling demonstrated that FNAR
gene expression was similar to that reported for human
ovarian carcinoma (Table 2). Metallothioneins are gener-
ally not found at immunohistochemically detectable
levels in normal cells, but their expression increases in
ovarian carcinoma with increasing grade [32-34]. Metal-
lothionein I was overexpressed 11.38-fold in FNAR cells
when compared to endothelial cells, and metallothionein
II showed 3.56-fold increased expression. Thioredoxin
expression correlates with cis-diaminedichloroplatinum
resistance [35] and is expressed in FNAR cells 3.07-fold
higher than in endothelial cells. Stathmin regulates
microtubules during the formation of the mitotic spindle
and is not expressed at detectable levels in normal cells;
however, high-level expression is generally seen in ovar-
ian carcinoma [36-38]. Accordingly, stathmin expression
was 3.23-fold higher in FNAR cells than in endothelial
cells. This data was confirmed by PCR (data not shown).
A nuclear factor that it is involved in cell cycle progres-
sion, b-myb, is also highly expressed in both FNAR cells
(3.33-fold) and human ovarian carcinoma [39].
High levels of interleukin-6 (IL-6), a proinflammatory
cytokine and hematopoietic growth factor, are found in
both normal ovarian epithelium and human ovarian
carcinoma [40,41]. Interleukin-18 (IL-18) is a proin-
flammatory cytokine that stimulates interferon-g pro-
duction. Ovarian carcinoma expresses IL-18, but it is
predominantly the pro-IL-18 form [42]. Interleukin-12
(IL-12) is a cytokine that encourages a Th1i m m u n e
response. IL-12 has been detected in ascites fluid and
serum of ovarian cancer patients [43], although no
reports have examined the expression of IL-12 by the
ovarian carcinoma cells themselves. Expression of all
three cytokines by FNAR cells was detected by real
time RT-PCR (Figure 5).
Discussion
We present here a model of ovarian carcinoma, desig-
nated FNAR, that arose spontaneously in a normal
Lewis rat. Importantly, FNAR’s biology closely parallels
the human disease. IP transplantation into rats pro-
duces malignant ascites and peritoneal carcinomatosis,
leading to death at 5-6 months. The tumor only devel-
ops in the peritoneal cavity, suggesting the tumor
Figure 4 FNAR expression of b-catenin. FNAR cells were stained with (A) b-catenin and (B) DAPI. The third panel (C) shows an overlay of the
two images.
Table 2 Gene chip analysis of FNAR.
Gene Expression Profiling of FNAR Cells
Gene Description EST Accession # Relative Expression
Metallothionein I AW141679 11.38
Metallothionein II AW916991 3.56
Thioredoxin AW140607 3.07
Stathmin BF281472 3.23
b-myb RGIAC37 3.33
Gene chip analysis of FNAR shows similarities to human ovarian carcinoma.
RNA was harvested from FNAR and REH endothelial cell lines and analyzed by
GeneChip at a Johns Hopkins core facility. Data are presented as the relative
expression of the gene in FNAR compared to expression in endothelial cells.
Figure 5 FNAR expression of IL-6, IL-12, and IL-18. FNAR tumor
cells express IL-6, IL-12, and IL-18. Expression was assessed by qPCR.
Data are standardized against GAPDH.
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from the tumor can be easily passaged in vitro,a n d
the cell line shows similar growth characteristics when
returned to rats. Its morphology and expression of
EPCAM are consistent with an epithelial carcinoma,
and like human ovarian carcinoma, it expresses her-2/
neu, sex hormone receptors, and characteristic cyto-
kines. FNAR also displays a similar gene expression
pattern to the human disease. Consistent with the
endometrioid subtype, FNAR cells show cell-surface
expression of CA125 and nuclear expression of b-
catenin.
The FNAR model may address many of the limitation
of current model systems for ovarian carcinoma. Rats
transplanted with FNAR consistently become moribund
by 5-6 months, avoiding the low frequency and long
latency of spontaneous animal models. Xenografts of
primary human tumors in immunodeficient mice are
perhaps the most attractive current model [16-19].
Although spontaneous human cancers can be studied
and used to test treatments in these mice, the study of
immunotherapeutic approaches is problematic. Conver-
sely, FNAR develops in immunocompetent rats, allowing
the study of immunotherapeutic approaches. The
expression of all three sex hormone receptors and her-
2/neu also allows for manipulations of these pathways
using this model. However, the application of this
model to the treatment of human disease remains to be
established.
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